Company Profile

Jaden BioScience Inc
Profile last edited on: 4/22/19      CAGE: 5LSX9      UEI:

Business Identifier: Blood tests for cancer
Year Founded
2005
First Award
2010
Latest Award
2013
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3950 Sorrento Valley Boulevard Suite 400
San Diego, CA 92121
   (858) 320-0097
   N/A
   www.jadenbio.com
Location: Single
Congr. District: 52
County: San Diego

Public Profile

Follwing the death of the firm's Founder, David E Kohne, the firm ceased operations. Jaden BioScience Inc. (Jaden) had specialized in developing and commercializing novel ultrasensitive in vitro research diagnostic assays for the scientific and medical communities. Jaden's core technology was ultrasensitive chemiluminescent signal generation and detection systems capable of detecting 5 enzyme molecules in 5 microliters. These technology platforms can be applied to detect either protein or nucleic acid analytes. The firm's assays target PCR level sensitivity without signal-amplification or the use of costly equipment and highly trained laboratory technicians. Jaden's detection technology had been adapted into simple to use assay formats using either 96 well microtiter plates or test tubes. Jaden's assays are performed in less than one hour. Jaden's first commercial research products are focused on the detection of cells and rare proteins. The company's technology ihad been designed to facilitate the identification of biomarkers and diagnostic markers that can be used to enable scientific discoveries, and in the development of pharmaceutical drugs and ultimately, individual patient management. Jaden developed ultrasensitive diagnostic platforms that are targeting PCR level sensitivity. This technology can be applied to proteins or nucleic acid analyte detection. Jaden is currently focusing on cell surface protein detection. Unlike flow cytometry methods, Jaden's platform does not require expensive equipment, doe not require a large sample size (1000 cells are sufficient), does not require highly trained technicians and can be run in resource limited laboratories.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $451,435
Project Title: Rare Protein Detection on Cell Surfaces: Ultrasensitive Detection of B-Cell Chron

Key People / Management

  Connie J Kohne -- President & Chief Executive Officer

Company News

There are no news available.